Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Xeloda To Be Reimbursed By Medicare As Prodrug Of 5-FU

Executive Summary

Roche's oral treatment for late-stage metastatic breast cancer Xeloda (capecitabine) will be covered for outpatient use by Medicare effective Jan. 1, 1999, the company announced Jan 13.

You may also be interested in...



Roche Xeloda Medicare Part B Reimbursement Raised To 90% Of AWP

Roche's oncologic Xeloda will be reimbursed at 90% of the average wholesale price under Medicare Part B

Roche Xeloda Medicare Part B Reimbursement Raised To 90% Of AWP

Roche's oncologic Xeloda will be reimbursed at 90% of the average wholesale price under Medicare Part B

Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing

Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich

UsernamePublicRestriction

Register

PS033493

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel